Cue Biopharma (CUE) Non-Current Debt (2022 - 2025)

Cue Biopharma has disclosed Non-Current Debt across 4 years of filings, most recently posting $190000.0 for Q3 2025.

• Non-Current Debt for Q3 2025 came in at $190000.0, down 85.69% year-over-year; the trailing twelve-month figure through Sep 2025 was $190000.0 (down 85.69% YoY), and the FY2023 annual result was $4.2 million, down 47.7% from the prior year.
• Non-Current Debt came in at $190000.0 for Q3 2025 at Cue Biopharma, roughly flat from $190000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.9 million in Q2 2022 to a low of $190000.0 in Q2 2025.
• The 4-year median for Non-Current Debt is $5.2 million (2023), against an average of $5.1 million.
• Across the five-year window, Non-Current Debt decreased 28.23% in 2023 and sank 91.69% in 2025, its largest moves.
• Cue Biopharma's Non-Current Debt stood at $8.0 million in 2022, then tumbled by 47.7% to $4.2 million in 2023, then slumped by 68.4% to $1.3 million in 2024, then sank by 85.69% to $190000.0 in 2025.
• The last three Non-Current Debt figures came in at $190000.0 (Q3 2025), $190000.0 (Q2 2025), and $1.3 million (Q3 2024), per Business Quant data.